BBZA Stock Overview
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
BB Biotech AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF49.40 |
52 Week High | CHF54.20 |
52 Week Low | CHF36.70 |
Beta | 0.84 |
1 Month Change | -3.14% |
3 Month Change | 15.42% |
1 Year Change | -8.69% |
3 Year Change | -39.16% |
5 Year Change | -21.77% |
Change since IPO | -81.22% |
Recent News & Updates
Recent updates
Shareholder Returns
BBZA | DE Capital Markets | DE Market | |
---|---|---|---|
7D | -2.0% | 1.4% | 0.4% |
1Y | -8.7% | 20.9% | 6.7% |
Return vs Industry: BBZA underperformed the German Capital Markets industry which returned 20.9% over the past year.
Return vs Market: BBZA underperformed the German Market which returned 6.7% over the past year.
Price Volatility
BBZA volatility | |
---|---|
BBZA Average Weekly Movement | 4.4% |
Capital Markets Industry Average Movement | 4.2% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BBZA has not had significant price volatility in the past 3 months.
Volatility Over Time: BBZA's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 10 | n/a | https://www.bbbiotech.ch/en/bb-biotech/ |
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.
BB Biotech AG Fundamentals Summary
BBZA fundamental statistics | |
---|---|
Market cap | €2.74b |
Earnings (TTM) | -€214.77m |
Revenue (TTM) | €36.38k |
Over9,999x
P/S Ratio-12.8x
P/E RatioIs BBZA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BBZA income statement (TTM) | |
---|---|
Revenue | CHF35.00k |
Cost of Revenue | CHF0 |
Gross Profit | CHF35.00k |
Other Expenses | CHF206.64m |
Earnings | -CHF206.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
Earnings per share (EPS) | -3.77 |
Gross Margin | 100.00% |
Net Profit Margin | -590,305.71% |
Debt/Equity Ratio | 13.1% |
How did BBZA perform over the long term?
See historical performance and comparisonDividends
4.2%
Current Dividend Yield-53%
Payout RatioDoes BBZA pay a reliable dividends?
See BBZA dividend history and benchmarksBB Biotech dividend dates | |
---|---|
Ex Dividend Date | Mar 25 2024 |
Dividend Pay Date | Mar 27 2024 |
Days until Ex dividend | 7 days |
Days until Dividend pay date | 9 days |
Does BBZA pay a reliable dividends?
See BBZA dividend history and benchmarks